Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 Apr 29 | 2022Gilead’s Oncology Deep Dive 2022: Celltelligence Analysis - Part 2Access Free BlastFree
Posted in: Autologous, TCR Apr 27 | 2022No Updates for GSK's Cell Therapy Assets; New GSK Expected to Launch in July 2022; GSK’s Q1 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD123, CD19 Apr 27 | 2022Kymriah's Sales Decline; PHE885 Pivotal Study Initiated; YTB323’s Anticipated Submission Delayed to 2025; Novartis’s Q1 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 25 | 2022Autolus’s Obe-cel Receives FDA RMAT Designation; JNJ / Legend Update Carvykti’s HCP WebsiteAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 22 | 2022CHMP Adopts Positive Opinion for Yescarta in ≥4L FL; Yescarta in 2L DLBCL Absent from April’s CHMP MeetingAccess Free BlastFree
Posted in: Autologous, BCMA Apr 21 | 2022Legend Achieves Another Milestone Payment from Janssen for CarvyktiAccess Free BlastFree
Posted in: BCMA, CAR-T Apr 20 | 2022Is Carvykti’s Launch Constrained by JNJ’s Manufacturing Capacity? JNJ Q1 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 19 | 2022Could Yescarta in r/r FL Receive a CHMP Positive Opinion This Week?Access Free BlastFree
Posted in: Allogeneic, Autologous, CD19, Other Apr 15 | 2022Gilead’s Oncology Deep Dive 2022: Celltelligence Analysis - Part 1Access Free BlastFree
Posted in: Autologous, CAR-T, TCR Apr 14 | 2022Fate’s Novel FT573 Pan-Tumor Targeting Asset and Tri-Modal CAR-TCR Platform; Shoreline’s iPSC-derived Screening Platform; BMS’s Abecma to be Reimbursed in Japan on April 20; AACR 2022 Final AnalysisAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Apr 13 | 2022Different Strategies for Enhancing CAR-Ts to Treat Solid Tumors; Preclinical Results from Allogene’s ALLO-316; TCR2 Tx’s Allogeneic TRuC-T Platform; AACR 2022 Analysis 4Access Free BlastFree
Posted in: Autologous, CAR-T, CD19, Dual/triple agonist Apr 12 | 2022Yescarta and Kymriah Product Attributes; Early Results from Gracell’s GC502 Ph1 Study in r/r B-ALL; Legend’s LB1901 Ph1 Study Design in r/r TCL; AACR 2022 Analysis 3Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD22 Apr 11 | 2022Preclinical Results from 2seventy’s bbT369 and Cellectis’s UCART20x22 for r/r NHL; Switchable CAR-T Updates from Arcellx and Roche; AACR 2022 Analysis 2Access Free BlastFree
Posted in: Allogeneic, CAR-T, Dual/triple agonist Apr 10 | 2022How Engineered CAR-NK Cells Could Overcome Several Major Challenges Faced by CAR-Ts; Nkarta and CRISPR Tx Report Preclinical Data for Developing a CD70 CAR-NK and a NK:T Treatment; AACR 2022 Analysis 1Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 08 | 2022Thoughts on Breyanzi’s sNDA Acceptance in Japan for 2L LBCLAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 04 | 2022Thoughts on Yescarta's FDA Approval in 2L LBCLAccess Free BlastFree
Posted in: Autologous, CD19 Apr 01 | 2022Yescarta Becomes the First Approved CAR-T for 2L LBCL in the USAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 25 | 2022CHMP Adopts Positive Opinions for Kymriah and Carvykti; Tecartus Absent From March’s CHMP HighlightsAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Mar 25 | 2022Breyanzi’s sNDA Accepted in Japan for 2L DLBCLAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Mar 24 | 2022Thoughts on Chinese CAR-T Ambitions after Lilly CRL and ODACAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.